Dental Patient Care America, Inc.
Dental Patient Care America, Inc. (DPAT) Stock Competitors & Peer Comparison
See (DPAT) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DPAT | $0.06 | +0.00% | 1.3M | -1.86 | -$0.03 | N/A |
| FSNUY | $11.98 | -2.04% | 107.8B | 14.95 | $0.80 | +2.36% |
| FSNUF | $54.35 | +0.00% | 30.6B | 17.09 | $3.18 | +2.08% |
| JDHIY | $6.85 | +0.00% | 22B | 27.40 | $0.25 | N/A |
| JDHIF | $5.85 | +0.00% | 18.8B | 23.40 | $0.25 | N/A |
| IHHHF | $1.71 | +0.00% | 15.1B | 28.50 | $0.06 | +1.52% |
| FMCQF | $43.08 | -2.64% | 12B | 10.93 | $3.94 | +3.79% |
| BDULF | $0.66 | +0.00% | 10.5B | 22.00 | $0.03 | +4.83% |
| BDUUF | $0.65 | +0.00% | 10.3B | 21.67 | $0.03 | +4.91% |
| BDUUY | $23.41 | +0.00% | 9.3B | 19.03 | $1.23 | +5.43% |
Stock Comparison
DPAT vs FSNUY Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, FSNUY has a market cap of 107.8B. Regarding current trading prices, DPAT is priced at $0.06, while FSNUY trades at $11.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas FSNUY's P/E ratio is 14.95. In terms of profitability, DPAT's ROE is +0.59%, compared to FSNUY's ROE of +0.07%. Regarding short-term risk, DPAT is less volatile compared to FSNUY. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check FSNUY's competition here
DPAT vs FSNUF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, FSNUF has a market cap of 30.6B. Regarding current trading prices, DPAT is priced at $0.06, while FSNUF trades at $54.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas FSNUF's P/E ratio is 17.09. In terms of profitability, DPAT's ROE is +0.59%, compared to FSNUF's ROE of +0.07%. Regarding short-term risk, DPAT is less volatile compared to FSNUF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check FSNUF's competition here
DPAT vs JDHIY Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, JDHIY has a market cap of 22B. Regarding current trading prices, DPAT is priced at $0.06, while JDHIY trades at $6.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas JDHIY's P/E ratio is 27.40. In terms of profitability, DPAT's ROE is +0.59%, compared to JDHIY's ROE of +0.09%. Regarding short-term risk, DPAT is less volatile compared to JDHIY. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check JDHIY's competition here
DPAT vs JDHIF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, JDHIF has a market cap of 18.8B. Regarding current trading prices, DPAT is priced at $0.06, while JDHIF trades at $5.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas JDHIF's P/E ratio is 23.40. In terms of profitability, DPAT's ROE is +0.59%, compared to JDHIF's ROE of +0.09%. Regarding short-term risk, DPAT is more volatile compared to JDHIF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check JDHIF's competition here
DPAT vs IHHHF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, IHHHF has a market cap of 15.1B. Regarding current trading prices, DPAT is priced at $0.06, while IHHHF trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas IHHHF's P/E ratio is 28.50. In terms of profitability, DPAT's ROE is +0.59%, compared to IHHHF's ROE of +0.07%. Regarding short-term risk, DPAT is more volatile compared to IHHHF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check IHHHF's competition here
DPAT vs FMCQF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, FMCQF has a market cap of 12B. Regarding current trading prices, DPAT is priced at $0.06, while FMCQF trades at $43.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas FMCQF's P/E ratio is 10.93. In terms of profitability, DPAT's ROE is +0.59%, compared to FMCQF's ROE of +0.07%. Regarding short-term risk, DPAT is more volatile compared to FMCQF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check FMCQF's competition here
DPAT vs BDULF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, BDULF has a market cap of 10.5B. Regarding current trading prices, DPAT is priced at $0.06, while BDULF trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas BDULF's P/E ratio is 22.00. In terms of profitability, DPAT's ROE is +0.59%, compared to BDULF's ROE of +0.15%. Regarding short-term risk, DPAT is more volatile compared to BDULF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BDULF's competition here
DPAT vs BDUUF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, BDUUF has a market cap of 10.3B. Regarding current trading prices, DPAT is priced at $0.06, while BDUUF trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas BDUUF's P/E ratio is 21.67. In terms of profitability, DPAT's ROE is +0.59%, compared to BDUUF's ROE of +0.15%. Regarding short-term risk, DPAT is less volatile compared to BDUUF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check BDUUF's competition here
DPAT vs BDUUY Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, BDUUY has a market cap of 9.3B. Regarding current trading prices, DPAT is priced at $0.06, while BDUUY trades at $23.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas BDUUY's P/E ratio is 19.03. In terms of profitability, DPAT's ROE is +0.59%, compared to BDUUY's ROE of +0.15%. Regarding short-term risk, DPAT is less volatile compared to BDUUY. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check BDUUY's competition here
DPAT vs RMYHY Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, RMYHY has a market cap of 6.7B. Regarding current trading prices, DPAT is priced at $0.06, while RMYHY trades at $7.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas RMYHY's P/E ratio is 31.83. In terms of profitability, DPAT's ROE is +0.59%, compared to RMYHY's ROE of +0.06%. Regarding short-term risk, DPAT is more volatile compared to RMYHY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check RMYHY's competition here
DPAT vs RMSYF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, RMSYF has a market cap of 5.7B. Regarding current trading prices, DPAT is priced at $0.06, while RMSYF trades at $24.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas RMSYF's P/E ratio is 356.71. In terms of profitability, DPAT's ROE is +0.59%, compared to RMSYF's ROE of +0.06%. Regarding short-term risk, DPAT is more volatile compared to RMSYF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check RMSYF's competition here
DPAT vs BUHPF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, BUHPF has a market cap of 4.3B. Regarding current trading prices, DPAT is priced at $0.06, while BUHPF trades at $5.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas BUHPF's P/E ratio is 20.19. In terms of profitability, DPAT's ROE is +0.59%, compared to BUHPF's ROE of +0.25%. Regarding short-term risk, DPAT is more volatile compared to BUHPF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BUHPF's competition here
DPAT vs MCVEF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, MCVEF has a market cap of 4.1B. Regarding current trading prices, DPAT is priced at $0.06, while MCVEF trades at $27.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas MCVEF's P/E ratio is 52.40. In terms of profitability, DPAT's ROE is +0.59%, compared to MCVEF's ROE of +0.15%. Regarding short-term risk, DPAT is less volatile compared to MCVEF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check MCVEF's competition here
DPAT vs ANHGY Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, ANHGY has a market cap of 4B. Regarding current trading prices, DPAT is priced at $0.06, while ANHGY trades at $5.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas ANHGY's P/E ratio is 23.87. In terms of profitability, DPAT's ROE is +0.59%, compared to ANHGY's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to ANHGY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check ANHGY's competition here
DPAT vs BUGDF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, BUGDF has a market cap of 3.8B. Regarding current trading prices, DPAT is priced at $0.06, while BUGDF trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas BUGDF's P/E ratio is 16.96. In terms of profitability, DPAT's ROE is +0.59%, compared to BUGDF's ROE of +0.25%. Regarding short-term risk, DPAT is more volatile compared to BUGDF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BUGDF's competition here
DPAT vs MCVEY Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, MCVEY has a market cap of 2.5B. Regarding current trading prices, DPAT is priced at $0.06, while MCVEY trades at $16.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas MCVEY's P/E ratio is 40.37. In terms of profitability, DPAT's ROE is +0.59%, compared to MCVEY's ROE of +0.16%. Regarding short-term risk, DPAT is less volatile compared to MCVEY. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check MCVEY's competition here
DPAT vs ORPEF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, ORPEF has a market cap of 2.3B. Regarding current trading prices, DPAT is priced at $0.06, while ORPEF trades at $14.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas ORPEF's P/E ratio is 0.03. In terms of profitability, DPAT's ROE is +0.59%, compared to ORPEF's ROE of -0.20%. Regarding short-term risk, DPAT is less volatile compared to ORPEF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check ORPEF's competition here
DPAT vs EXETF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, EXETF has a market cap of 2.1B. Regarding current trading prices, DPAT is priced at $0.06, while EXETF trades at $22.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas EXETF's P/E ratio is 27.60. In terms of profitability, DPAT's ROE is +0.59%, compared to EXETF's ROE of +0.48%. Regarding short-term risk, DPAT is less volatile compared to EXETF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check EXETF's competition here
DPAT vs LWSCF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, LWSCF has a market cap of 1.7B. Regarding current trading prices, DPAT is priced at $0.06, while LWSCF trades at $17.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas LWSCF's P/E ratio is 47.25. In terms of profitability, DPAT's ROE is +0.59%, compared to LWSCF's ROE of +0.07%. Regarding short-term risk, DPAT is less volatile compared to LWSCF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check LWSCF's competition here
DPAT vs RAFLF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, RAFLF has a market cap of 1.5B. Regarding current trading prices, DPAT is priced at $0.06, while RAFLF trades at $0.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas RAFLF's P/E ratio is 26.67. In terms of profitability, DPAT's ROE is +0.59%, compared to RAFLF's ROE of +0.05%. Regarding short-term risk, DPAT is less volatile compared to RAFLF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check RAFLF's competition here
DPAT vs RHCGF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, RHCGF has a market cap of 1.4B. Regarding current trading prices, DPAT is priced at $0.06, while RHCGF trades at $1.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas RHCGF's P/E ratio is -5.04. In terms of profitability, DPAT's ROE is +0.59%, compared to RHCGF's ROE of -0.14%. Regarding short-term risk, DPAT is less volatile compared to RHCGF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check RHCGF's competition here
DPAT vs TTALF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, TTALF has a market cap of 1.1B. Regarding current trading prices, DPAT is priced at $0.06, while TTALF trades at $8.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas TTALF's P/E ratio is 12.43. In terms of profitability, DPAT's ROE is +0.59%, compared to TTALF's ROE of +0.14%. Regarding short-term risk, DPAT is less volatile compared to TTALF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check TTALF's competition here
DPAT vs RKAGY Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, RKAGY has a market cap of 1.1B. Regarding current trading prices, DPAT is priced at $0.06, while RKAGY trades at $8.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas RKAGY's P/E ratio is 24.73. In terms of profitability, DPAT's ROE is +0.59%, compared to RKAGY's ROE of +0.03%. Regarding short-term risk, DPAT is more volatile compared to RKAGY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check RKAGY's competition here
DPAT vs LTGHY Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, LTGHY has a market cap of 1.1B. Regarding current trading prices, DPAT is priced at $0.06, while LTGHY trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas LTGHY's P/E ratio is -11.54. In terms of profitability, DPAT's ROE is +0.59%, compared to LTGHY's ROE of +0.38%. Regarding short-term risk, DPAT is less volatile compared to LTGHY. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check LTGHY's competition here
DPAT vs RYHTY Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, RYHTY has a market cap of 1.1B. Regarding current trading prices, DPAT is priced at $0.06, while RYHTY trades at $6.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas RYHTY's P/E ratio is -4.59. In terms of profitability, DPAT's ROE is +0.59%, compared to RYHTY's ROE of -0.14%. Regarding short-term risk, DPAT is more volatile compared to RYHTY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check RYHTY's competition here
DPAT vs RHKJF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, RHKJF has a market cap of 1B. Regarding current trading prices, DPAT is priced at $0.06, while RHKJF trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas RHKJF's P/E ratio is 21.55. In terms of profitability, DPAT's ROE is +0.59%, compared to RHKJF's ROE of +0.03%. Regarding short-term risk, DPAT is more volatile compared to RHKJF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check RHKJF's competition here
DPAT vs LTGHF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, LTGHF has a market cap of 978.7M. Regarding current trading prices, DPAT is priced at $0.06, while LTGHF trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas LTGHF's P/E ratio is -11.40. In terms of profitability, DPAT's ROE is +0.59%, compared to LTGHF's ROE of +8.48%. Regarding short-term risk, DPAT is less volatile compared to LTGHF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check LTGHF's competition here
DPAT vs NWKHY Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, NWKHY has a market cap of 854.5M. Regarding current trading prices, DPAT is priced at $0.06, while NWKHY trades at $7.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas NWKHY's P/E ratio is 10.39. In terms of profitability, DPAT's ROE is +0.59%, compared to NWKHY's ROE of +0.16%. Regarding short-term risk, DPAT is more volatile compared to NWKHY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NWKHY's competition here
DPAT vs WHTCF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, WHTCF has a market cap of 812.4M. Regarding current trading prices, DPAT is priced at $0.06, while WHTCF trades at $3.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas WHTCF's P/E ratio is -159.00. In terms of profitability, DPAT's ROE is +0.59%, compared to WHTCF's ROE of -0.01%. Regarding short-term risk, DPAT is less volatile compared to WHTCF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check WHTCF's competition here
DPAT vs JXFGF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, JXFGF has a market cap of 770.4M. Regarding current trading prices, DPAT is priced at $0.06, while JXFGF trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas JXFGF's P/E ratio is -5.80. In terms of profitability, DPAT's ROE is +0.59%, compared to JXFGF's ROE of -0.11%. Regarding short-term risk, DPAT is less volatile compared to JXFGF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check JXFGF's competition here
DPAT vs KDGTF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, KDGTF has a market cap of 675.1M. Regarding current trading prices, DPAT is priced at $0.06, while KDGTF trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas KDGTF's P/E ratio is -1.67. In terms of profitability, DPAT's ROE is +0.59%, compared to KDGTF's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to KDGTF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check KDGTF's competition here
DPAT vs WFHG Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, WFHG has a market cap of 472.5M. Regarding current trading prices, DPAT is priced at $0.06, while WFHG trades at $7.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas WFHG's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to WFHG's ROE of +0.00%. Regarding short-term risk, DPAT is more volatile compared to WFHG. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check WFHG's competition here
DPAT vs ORRRY Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, ORRRY has a market cap of 371.5M. Regarding current trading prices, DPAT is priced at $0.06, while ORRRY trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas ORRRY's P/E ratio is -0.33. In terms of profitability, DPAT's ROE is +0.59%, compared to ORRRY's ROE of +7.04%. Regarding short-term risk, DPAT is more volatile compared to ORRRY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check ORRRY's competition here
DPAT vs BTMDW Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, BTMDW has a market cap of 292.9M. Regarding current trading prices, DPAT is priced at $0.06, while BTMDW trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas BTMDW's P/E ratio is 0.05. In terms of profitability, DPAT's ROE is +0.59%, compared to BTMDW's ROE of -0.35%. Regarding short-term risk, DPAT is less volatile compared to BTMDW. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check BTMDW's competition here
DPAT vs MFCSF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, MFCSF has a market cap of 221M. Regarding current trading prices, DPAT is priced at $0.06, while MFCSF trades at $12.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas MFCSF's P/E ratio is 15.91. In terms of profitability, DPAT's ROE is +0.59%, compared to MFCSF's ROE of +0.27%. Regarding short-term risk, DPAT is more volatile compared to MFCSF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check MFCSF's competition here
DPAT vs MKLNF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, MKLNF has a market cap of 214.8M. Regarding current trading prices, DPAT is priced at $0.06, while MKLNF trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas MKLNF's P/E ratio is 19.23. In terms of profitability, DPAT's ROE is +0.59%, compared to MKLNF's ROE of +0.16%. Regarding short-term risk, DPAT is more volatile compared to MKLNF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check MKLNF's competition here
DPAT vs HWAIF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, HWAIF has a market cap of 211.1M. Regarding current trading prices, DPAT is priced at $0.06, while HWAIF trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas HWAIF's P/E ratio is -6.54. In terms of profitability, DPAT's ROE is +0.59%, compared to HWAIF's ROE of -0.39%. Regarding short-term risk, DPAT is less volatile compared to HWAIF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check HWAIF's competition here
DPAT vs CHHHF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, CHHHF has a market cap of 169.2M. Regarding current trading prices, DPAT is priced at $0.06, while CHHHF trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas CHHHF's P/E ratio is 8.97. In terms of profitability, DPAT's ROE is +0.59%, compared to CHHHF's ROE of +0.28%. Regarding short-term risk, DPAT is more volatile compared to CHHHF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check CHHHF's competition here
DPAT vs COLRF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, COLRF has a market cap of 123M. Regarding current trading prices, DPAT is priced at $0.06, while COLRF trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas COLRF's P/E ratio is -8.00. In terms of profitability, DPAT's ROE is +0.59%, compared to COLRF's ROE of +0.00%. Regarding short-term risk, DPAT is less volatile compared to COLRF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check COLRF's competition here
DPAT vs VTIAF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, VTIAF has a market cap of 111.1M. Regarding current trading prices, DPAT is priced at $0.06, while VTIAF trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas VTIAF's P/E ratio is -9.11. In terms of profitability, DPAT's ROE is +0.59%, compared to VTIAF's ROE of -0.53%. Regarding short-term risk, DPAT is less volatile compared to VTIAF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check VTIAF's competition here
DPAT vs TOKIF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, TOKIF has a market cap of 101.4M. Regarding current trading prices, DPAT is priced at $0.06, while TOKIF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas TOKIF's P/E ratio is -0.57. In terms of profitability, DPAT's ROE is +0.59%, compared to TOKIF's ROE of -0.83%. Regarding short-term risk, DPAT is less volatile compared to TOKIF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check TOKIF's competition here
DPAT vs MCIOF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, MCIOF has a market cap of 54M. Regarding current trading prices, DPAT is priced at $0.06, while MCIOF trades at $0.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas MCIOF's P/E ratio is -1.22. In terms of profitability, DPAT's ROE is +0.59%, compared to MCIOF's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to MCIOF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check MCIOF's competition here
DPAT vs NAFS Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, NAFS has a market cap of 49.1M. Regarding current trading prices, DPAT is priced at $0.06, while NAFS trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas NAFS's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to NAFS's ROE of +0.31%. Regarding short-term risk, DPAT is more volatile compared to NAFS. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NAFS's competition here
DPAT vs ASSF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, ASSF has a market cap of 45.3M. Regarding current trading prices, DPAT is priced at $0.06, while ASSF trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas ASSF's P/E ratio is -33.33. In terms of profitability, DPAT's ROE is +0.59%, compared to ASSF's ROE of -6.63%. Regarding short-term risk, DPAT is more volatile compared to ASSF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check ASSF's competition here
DPAT vs NVLPF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, NVLPF has a market cap of 24.4M. Regarding current trading prices, DPAT is priced at $0.06, while NVLPF trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas NVLPF's P/E ratio is 28.00. In terms of profitability, DPAT's ROE is +0.59%, compared to NVLPF's ROE of -0.01%. Regarding short-term risk, DPAT is more volatile compared to NVLPF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NVLPF's competition here
DPAT vs USNU Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, USNU has a market cap of 22.2M. Regarding current trading prices, DPAT is priced at $0.06, while USNU trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas USNU's P/E ratio is -9.41. In terms of profitability, DPAT's ROE is +0.59%, compared to USNU's ROE of -1.70%. Regarding short-term risk, DPAT is less volatile compared to USNU. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check USNU's competition here
DPAT vs HQDA Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, HQDA has a market cap of 18.6M. Regarding current trading prices, DPAT is priced at $0.06, while HQDA trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas HQDA's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to HQDA's ROE of -0.06%. Regarding short-term risk, DPAT is more volatile compared to HQDA. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check HQDA's competition here
DPAT vs EVGRF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, EVGRF has a market cap of 11.9M. Regarding current trading prices, DPAT is priced at $0.06, while EVGRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas EVGRF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to EVGRF's ROE of +0.22%. Regarding short-term risk, DPAT is less volatile compared to EVGRF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check EVGRF's competition here
DPAT vs GBCS Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, GBCS has a market cap of 11M. Regarding current trading prices, DPAT is priced at $0.06, while GBCS trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas GBCS's P/E ratio is -10.56. In terms of profitability, DPAT's ROE is +0.59%, compared to GBCS's ROE of +0.17%. Regarding short-term risk, DPAT is less volatile compared to GBCS. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check GBCS's competition here
DPAT vs FPCG Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, FPCG has a market cap of 10.1M. Regarding current trading prices, DPAT is priced at $0.06, while FPCG trades at $1,025.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas FPCG's P/E ratio is 0.09. In terms of profitability, DPAT's ROE is +0.59%, compared to FPCG's ROE of +0.00%. Regarding short-term risk, DPAT is more volatile compared to FPCG. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check FPCG's competition here
DPAT vs XCRT Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, XCRT has a market cap of 8M. Regarding current trading prices, DPAT is priced at $0.06, while XCRT trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas XCRT's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to XCRT's ROE of +0.26%. Regarding short-term risk, DPAT is less volatile compared to XCRT. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check XCRT's competition here
DPAT vs HLYK Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, HLYK has a market cap of 7.4M. Regarding current trading prices, DPAT is priced at $0.06, while HLYK trades at $2.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas HLYK's P/E ratio is -2.16. In terms of profitability, DPAT's ROE is +0.59%, compared to HLYK's ROE of +0.65%. Regarding short-term risk, DPAT is less volatile compared to HLYK. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check HLYK's competition here
DPAT vs NUMIF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, NUMIF has a market cap of 6.7M. Regarding current trading prices, DPAT is priced at $0.06, while NUMIF trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas NUMIF's P/E ratio is -0.70. In terms of profitability, DPAT's ROE is +0.59%, compared to NUMIF's ROE of +11.51%. Regarding short-term risk, DPAT is more volatile compared to NUMIF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NUMIF's competition here
DPAT vs RVLWF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, RVLWF has a market cap of 5.4M. Regarding current trading prices, DPAT is priced at $0.06, while RVLWF trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas RVLWF's P/E ratio is -0.30. In terms of profitability, DPAT's ROE is +0.59%, compared to RVLWF's ROE of +3.95%. Regarding short-term risk, DPAT is more volatile compared to RVLWF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check RVLWF's competition here
DPAT vs VLXC Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, VLXC has a market cap of 4.9M. Regarding current trading prices, DPAT is priced at $0.06, while VLXC trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas VLXC's P/E ratio is -4.99. In terms of profitability, DPAT's ROE is +0.59%, compared to VLXC's ROE of +0.74%. Regarding short-term risk, DPAT is less volatile compared to VLXC. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check VLXC's competition here
DPAT vs BICX Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, BICX has a market cap of 4.5M. Regarding current trading prices, DPAT is priced at $0.06, while BICX trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas BICX's P/E ratio is -1.28. In terms of profitability, DPAT's ROE is +0.59%, compared to BICX's ROE of +0.28%. Regarding short-term risk, DPAT is more volatile compared to BICX. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BICX's competition here
DPAT vs RHEP Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, RHEP has a market cap of 3M. Regarding current trading prices, DPAT is priced at $0.06, while RHEP trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas RHEP's P/E ratio is 1.19. In terms of profitability, DPAT's ROE is +0.59%, compared to RHEP's ROE of -9.49%. Regarding short-term risk, DPAT is more volatile compared to RHEP. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check RHEP's competition here
DPAT vs EPWCF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, EPWCF has a market cap of 2.5M. Regarding current trading prices, DPAT is priced at $0.06, while EPWCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas EPWCF's P/E ratio is -0.00. In terms of profitability, DPAT's ROE is +0.59%, compared to EPWCF's ROE of +0.00%. Regarding short-term risk, DPAT is less volatile compared to EPWCF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check EPWCF's competition here
DPAT vs NRPR Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, NRPR has a market cap of 2.1M. Regarding current trading prices, DPAT is priced at $0.06, while NRPR trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas NRPR's P/E ratio is -0.03. In terms of profitability, DPAT's ROE is +0.59%, compared to NRPR's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to NRPR. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NRPR's competition here
DPAT vs SMAS Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, SMAS has a market cap of 1.5M. Regarding current trading prices, DPAT is priced at $0.06, while SMAS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas SMAS's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to SMAS's ROE of N/A. Regarding short-term risk, DPAT is less volatile compared to SMAS. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check SMAS's competition here
DPAT vs MDGP Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, MDGP has a market cap of 1.5M. Regarding current trading prices, DPAT is priced at $0.06, while MDGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas MDGP's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to MDGP's ROE of -2.19%. Regarding short-term risk, DPAT is more volatile compared to MDGP. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check MDGP's competition here
DPAT vs NOVC Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, NOVC has a market cap of 1.2M. Regarding current trading prices, DPAT is priced at $0.06, while NOVC trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas NOVC's P/E ratio is -0.20. In terms of profitability, DPAT's ROE is +0.59%, compared to NOVC's ROE of +0.12%. Regarding short-term risk, DPAT is more volatile compared to NOVC. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NOVC's competition here
DPAT vs PHMB Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, PHMB has a market cap of 1.1M. Regarding current trading prices, DPAT is priced at $0.06, while PHMB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas PHMB's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to PHMB's ROE of N/A. Regarding short-term risk, DPAT is less volatile compared to PHMB. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check PHMB's competition here
DPAT vs GNOW Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, GNOW has a market cap of 859.7K. Regarding current trading prices, DPAT is priced at $0.06, while GNOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas GNOW's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.59%, compared to GNOW's ROE of -12.49%. Regarding short-term risk, DPAT is more volatile compared to GNOW. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check GNOW's competition here
DPAT vs JRSS Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, JRSS has a market cap of 846K. Regarding current trading prices, DPAT is priced at $0.06, while JRSS trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas JRSS's P/E ratio is -0.10. In terms of profitability, DPAT's ROE is +0.59%, compared to JRSS's ROE of -0.07%. Regarding short-term risk, DPAT is more volatile compared to JRSS. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check JRSS's competition here
DPAT vs JNHMF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, JNHMF has a market cap of 779.5K. Regarding current trading prices, DPAT is priced at $0.06, while JNHMF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas JNHMF's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.59%, compared to JNHMF's ROE of -101.83%. Regarding short-term risk, DPAT is more volatile compared to JNHMF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check JNHMF's competition here
DPAT vs GRST Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, GRST has a market cap of 772.6K. Regarding current trading prices, DPAT is priced at $0.06, while GRST trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas GRST's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to GRST's ROE of +0.17%. Regarding short-term risk, DPAT is more volatile compared to GRST. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check GRST's competition here
DPAT vs KJFI Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, KJFI has a market cap of 490.1K. Regarding current trading prices, DPAT is priced at $0.06, while KJFI trades at $0.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas KJFI's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.59%, compared to KJFI's ROE of +0.00%. Regarding short-term risk, DPAT is more volatile compared to KJFI. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check KJFI's competition here
DPAT vs MSITF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, MSITF has a market cap of 480K. Regarding current trading prices, DPAT is priced at $0.06, while MSITF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas MSITF's P/E ratio is -0.10. In terms of profitability, DPAT's ROE is +0.59%, compared to MSITF's ROE of N/A. Regarding short-term risk, DPAT is less volatile compared to MSITF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check MSITF's competition here
DPAT vs MAHN Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, MAHN has a market cap of 459.8K. Regarding current trading prices, DPAT is priced at $0.06, while MAHN trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas MAHN's P/E ratio is 19.00. In terms of profitability, DPAT's ROE is +0.59%, compared to MAHN's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to MAHN. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check MAHN's competition here
DPAT vs ARPC Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, ARPC has a market cap of 336.6K. Regarding current trading prices, DPAT is priced at $0.06, while ARPC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas ARPC's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to ARPC's ROE of +3.10%. Regarding short-term risk, DPAT is less volatile compared to ARPC. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check ARPC's competition here
DPAT vs BNYN Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, BNYN has a market cap of 286K. Regarding current trading prices, DPAT is priced at $0.06, while BNYN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas BNYN's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to BNYN's ROE of -14.10%. Regarding short-term risk, DPAT is less volatile compared to BNYN. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check BNYN's competition here
DPAT vs NXGT Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, NXGT has a market cap of 236.7K. Regarding current trading prices, DPAT is priced at $0.06, while NXGT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas NXGT's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to NXGT's ROE of +0.03%. Regarding short-term risk, DPAT is more volatile compared to NXGT. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NXGT's competition here
DPAT vs SETO Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, SETO has a market cap of 234.5K. Regarding current trading prices, DPAT is priced at $0.06, while SETO trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas SETO's P/E ratio is -1.88. In terms of profitability, DPAT's ROE is +0.59%, compared to SETO's ROE of -0.15%. Regarding short-term risk, DPAT is more volatile compared to SETO. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check SETO's competition here
DPAT vs CLRD Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, CLRD has a market cap of 149.2K. Regarding current trading prices, DPAT is priced at $0.06, while CLRD trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas CLRD's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.59%, compared to CLRD's ROE of +0.38%. Regarding short-term risk, DPAT is less volatile compared to CLRD. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check CLRD's competition here
DPAT vs FCHS Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, FCHS has a market cap of 131.8K. Regarding current trading prices, DPAT is priced at $0.06, while FCHS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas FCHS's P/E ratio is -0.02. In terms of profitability, DPAT's ROE is +0.59%, compared to FCHS's ROE of +0.20%. Regarding short-term risk, DPAT is more volatile compared to FCHS. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check FCHS's competition here
DPAT vs TPIA Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, TPIA has a market cap of 113.8K. Regarding current trading prices, DPAT is priced at $0.06, while TPIA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas TPIA's P/E ratio is -0.15. In terms of profitability, DPAT's ROE is +0.59%, compared to TPIA's ROE of +0.56%. Regarding short-term risk, DPAT is less volatile compared to TPIA. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check TPIA's competition here
DPAT vs AMBD Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, AMBD has a market cap of 85.6K. Regarding current trading prices, DPAT is priced at $0.06, while AMBD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas AMBD's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to AMBD's ROE of +1.11%. Regarding short-term risk, DPAT is less volatile compared to AMBD. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check AMBD's competition here
DPAT vs NMHLY Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, NMHLY has a market cap of 41.7K. Regarding current trading prices, DPAT is priced at $0.06, while NMHLY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas NMHLY's P/E ratio is 0.02. In terms of profitability, DPAT's ROE is +0.59%, compared to NMHLY's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to NMHLY. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NMHLY's competition here
DPAT vs MSGP Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, MSGP has a market cap of 31.1K. Regarding current trading prices, DPAT is priced at $0.06, while MSGP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas MSGP's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to MSGP's ROE of +0.27%. Regarding short-term risk, DPAT is less volatile compared to MSGP. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check MSGP's competition here
DPAT vs DRWN Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, DRWN has a market cap of 24K. Regarding current trading prices, DPAT is priced at $0.06, while DRWN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas DRWN's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to DRWN's ROE of -0.01%. Regarding short-term risk, DPAT is less volatile compared to DRWN. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check DRWN's competition here
DPAT vs PRMD Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, PRMD has a market cap of 20.3K. Regarding current trading prices, DPAT is priced at $0.06, while PRMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas PRMD's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to PRMD's ROE of +0.73%. Regarding short-term risk, DPAT is less volatile compared to PRMD. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check PRMD's competition here
DPAT vs HSMD Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, HSMD has a market cap of 18.4K. Regarding current trading prices, DPAT is priced at $0.06, while HSMD trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas HSMD's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.59%, compared to HSMD's ROE of -0.04%. Regarding short-term risk, DPAT is more volatile compared to HSMD. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check HSMD's competition here
DPAT vs SCAL Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, SCAL has a market cap of 17.4K. Regarding current trading prices, DPAT is priced at $0.06, while SCAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas SCAL's P/E ratio is 0.04. In terms of profitability, DPAT's ROE is +0.59%, compared to SCAL's ROE of +0.07%. Regarding short-term risk, DPAT is more volatile compared to SCAL. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check SCAL's competition here
DPAT vs CEVE Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, CEVE has a market cap of 17.1K. Regarding current trading prices, DPAT is priced at $0.06, while CEVE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas CEVE's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to CEVE's ROE of +2.26%. Regarding short-term risk, DPAT is more volatile compared to CEVE. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check CEVE's competition here
DPAT vs GENN Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, GENN has a market cap of 12.1K. Regarding current trading prices, DPAT is priced at $0.06, while GENN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas GENN's P/E ratio is -0.01. In terms of profitability, DPAT's ROE is +0.59%, compared to GENN's ROE of +0.07%. Regarding short-term risk, DPAT is less volatile compared to GENN. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check GENN's competition here
DPAT vs CHCR Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, CHCR has a market cap of 12K. Regarding current trading prices, DPAT is priced at $0.06, while CHCR trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas CHCR's P/E ratio is -0.00. In terms of profitability, DPAT's ROE is +0.59%, compared to CHCR's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to CHCR. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check CHCR's competition here
DPAT vs ACGI Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, ACGI has a market cap of 10.5K. Regarding current trading prices, DPAT is priced at $0.06, while ACGI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas ACGI's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to ACGI's ROE of +1.11%. Regarding short-term risk, DPAT is less volatile compared to ACGI. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check ACGI's competition here
DPAT vs WEQL Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, WEQL has a market cap of 7.2K. Regarding current trading prices, DPAT is priced at $0.06, while WEQL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas WEQL's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to WEQL's ROE of +0.21%. Regarding short-term risk, DPAT is less volatile compared to WEQL. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check WEQL's competition here
DPAT vs SLHGF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, SLHGF has a market cap of 4K. Regarding current trading prices, DPAT is priced at $0.06, while SLHGF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas SLHGF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to SLHGF's ROE of -0.42%. Regarding short-term risk, DPAT is less volatile compared to SLHGF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check SLHGF's competition here
DPAT vs SLHPF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, SLHPF has a market cap of 3.9K. Regarding current trading prices, DPAT is priced at $0.06, while SLHPF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas SLHPF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to SLHPF's ROE of -0.42%. Regarding short-term risk, DPAT is less volatile compared to SLHPF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check SLHPF's competition here
DPAT vs ERUC Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, ERUC has a market cap of 3.9K. Regarding current trading prices, DPAT is priced at $0.06, while ERUC trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas ERUC's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to ERUC's ROE of N/A. Regarding short-term risk, DPAT is more volatile compared to ERUC. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check ERUC's competition here
DPAT vs PAOG Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, PAOG has a market cap of 3.7K. Regarding current trading prices, DPAT is priced at $0.06, while PAOG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas PAOG's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to PAOG's ROE of +0.03%. Regarding short-term risk, DPAT is less volatile compared to PAOG. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check PAOG's competition here
DPAT vs BBAL Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, BBAL has a market cap of 3.4K. Regarding current trading prices, DPAT is priced at $0.06, while BBAL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas BBAL's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to BBAL's ROE of +0.45%. Regarding short-term risk, DPAT is more volatile compared to BBAL. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BBAL's competition here
DPAT vs NMMCF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, NMMCF has a market cap of 2.1K. Regarding current trading prices, DPAT is priced at $0.06, while NMMCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas NMMCF's P/E ratio is 0.00. In terms of profitability, DPAT's ROE is +0.59%, compared to NMMCF's ROE of +0.21%. Regarding short-term risk, DPAT is more volatile compared to NMMCF. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check NMMCF's competition here
DPAT vs PPRG Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, PPRG has a market cap of 1.6K. Regarding current trading prices, DPAT is priced at $0.06, while PPRG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas PPRG's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to PPRG's ROE of -0.58%. Regarding short-term risk, DPAT is more volatile compared to PPRG. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check PPRG's competition here
DPAT vs KONEF Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, KONEF has a market cap of 1.6K. Regarding current trading prices, DPAT is priced at $0.06, while KONEF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas KONEF's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to KONEF's ROE of -6.56%. Regarding short-term risk, DPAT is less volatile compared to KONEF. This indicates potentially lower risk in terms of short-term price fluctuations for DPAT.Check KONEF's competition here
DPAT vs OHAQ Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, OHAQ has a market cap of 1.4K. Regarding current trading prices, DPAT is priced at $0.06, while OHAQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas OHAQ's P/E ratio is 0.01. In terms of profitability, DPAT's ROE is +0.59%, compared to OHAQ's ROE of +0.09%. Regarding short-term risk, DPAT is more volatile compared to OHAQ. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check OHAQ's competition here
DPAT vs BNKL Comparison May 2026
DPAT plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DPAT stands at 1.3M. In comparison, BNKL has a market cap of 1.2K. Regarding current trading prices, DPAT is priced at $0.06, while BNKL trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DPAT currently has a P/E ratio of -1.86, whereas BNKL's P/E ratio is N/A. In terms of profitability, DPAT's ROE is +0.59%, compared to BNKL's ROE of -7.69%. Regarding short-term risk, DPAT is more volatile compared to BNKL. This indicates potentially higher risk in terms of short-term price fluctuations for DPAT.Check BNKL's competition here